title: Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.
abstract: OBJECTIVE
  To investigate the effect of oral Rifampin in patients with chronic central serous chorioretinoapthy (CSCR).
  
  
  METHODS
  This was a prospective pilot study of patients with chronic CSCR with persistent subretinal fluid (SRF) for at least 3 months, who were treated with oral Rifampin 300 mg twice per day for 3 months and had 6 months of follow-up. All patients underwent a complete ocular examination and a spectral domain optical coherence tomography (SD-OCT) scan monthly from baseline until month 4, and then at month 6. Fluorescein angiography (FA) was performed at baseline and at the end of the study.
  
  
  RESULTS
  Fourteen eyes of 12 patients were included in the study, nine men and three women. Mean age was 58.5 years (range 32-80). Mean duration of SRF prior to study entry was 28.4 months. Forty-two percent of eyes were treated previously for CSR with thermal laser, PDT, or intravitreal bevacizumab. Mean best corrected visual acuity (BCVA) at presentation was 20/60 and improved to a mean of 20/50 at month 3 (P > 0.05). Retinal thickness was reduced by 25.3 %, 21.2 %, and 21 % on months 1, 2, 3, respectively (P < 0.05). Mean choroidal thickness at presentation was 476 μ (SD 188 μ) decreasing to 427 μ (SD 125 μ) after 3 months of treatment (P > 0.05). SRF was reduced in nine eyes (64 %) and completely resolved in six eyes (42.8 %) at month 3 following 3 months of treatment, and four out of these six eyes remained fluid free at month 6. Two patients stopped the treatment after 2 months due to adverse events.
  
  
  CONCLUSIONS
  Oral Rifampin may be a therapeutic option in patients with longstanding chronic CSCR.
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel. shulmanshiri@gmail.com.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. shulmanshiri@gmail.com.
authors: Shiri
authors: S
authors: Shulman
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Dafna
authors: D
authors: Goldenberg
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Roy
authors: R
authors: Schwartz
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Zohar
authors: Z
authors: Habot-Wilner
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Adiel
authors: A
authors: Barak
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Nurit
authors: N
authors: Ehrlich
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Anat
authors: A
authors: Loewenstein
authors: Department of Ophthalmology, Tel-Aviv Medical Center, 6 Weizman Street, Tel Aviv, 64239, Israel.|Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors: Michaella
authors: M
authors: Goldstein
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002908:Chronic Disease; D065701:Cytochrome P-450 CYP3A Inducers / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D012160:Retina / Q000473:pathology; D012293:Rifampin / Q000627:therapeutic use*; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology
chemical_list: D065701:Cytochrome P-450 CYP3A Inducers; D012293:Rifampin
keywords: Central Serous Chorioretinopathy; Cytochrome P450; Optical Coherence Tomography; Rifampin